文献速递脊柱关节炎其他结缔组织病

高密度脂蛋白相关对氧磷酶1活性与银屑病疾病中的系统性炎症、疾病活动度和心血管危险因素的相关性

Correlation of High-Density Lipoprotein-Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease.
PubMed 文献 · Arthritis Rheumatol · 2018-07-08

在纵向银屑病生物样本库中,比较银屑病(PsO,n=145)与银屑病关节炎(PsA,n=198)患者的高密度脂蛋白相关对氧磷酶1(PON1)活性。PsO和PsA患者的芳基酯酶活性均低于健康对照(P<0.001);在PsA队列中芳基酯酶活性降低与关节疾病活动和心血管病负担加重相关,但PsO队列无此相关性。

要点

  • PsO和PsA患者血清芳基酯酶活性均低于健康对照(P<0.001)。
  • PsA队列中芳基酯酶活性降低与DAS28评分升高、代谢综合征和高血压发生率增加及Framingham风险评分恶化相关。
  • PsO队列中芳基酯酶活性与疾病活动度或心血管病负担无相关性。

核心结论

  • PON1活性在银屑病疾病中降低。
  • 在PsA队列中,芳基酯酶活性降低与关节疾病严重程度和心血管病负担加重相关。
  • 芳基酯酶活性较对氧磷酶活性似乎是PsA队列中已有心血管危险因素的更敏感预测指标,但该相关性在PsO人群中未观察到。

研究设计与样本

  • 研究纳入纵向银屑病生物样本库中的PsA患者(n=198,男性51.0%)和PsO患者(n=145,男性50.3%),测量血清对氧磷酶和芳基酯酶活性(均为人类PON1功能指标)。
  • 记录PsA疾病活动度(DAS28、临床疾病活动指数、疼痛/肿胀关节计数)、已有心血管病及心血管病危险因素(包括糖尿病、血脂异常、高血压和吸烟)、Framingham心血管病风险评分、生活质量指标和实验室检查(红细胞沉降率、C反应蛋白和血脂谱)。

主要发现

  • PsO患者血清芳基酯酶活性均值±标准差为111.1±25.5 μmoles/minute/ml,PsA患者为124.4±33.4 μmoles/minute/ml,均低于健康对照的144.3±33.4 μmoles/minute/ml(各P<0.001 vs 健康对照)。
  • 在PsA队列中,血清芳基酯酶活性随DAS28评分升高(P=0.012)、年龄增长(P=0.013)、体重指数升高(P=0.042)、代谢综合征发生率增加(P=0.004)和高血压发生率增加(P=0.014)以及Framingham风险评分恶化(P=0.001)而平行降低。
  • PsO患者中血清芳基酯酶活性与疾病活动度或心血管病负担程度无相关性。
  • PsO和PsA患者血清对氧磷酶活性均呈较低趋势(各P=0.073 vs 健康对照),但两个患者队列中对氧磷酶活性与疾病活动度或心血管病负担均无关联。

关键数值与推荐

  • PsO患者芳基酯酶活性111.1±25.5 μmoles/minute/ml vs 健康对照144.3±33.4 μmoles/minute/ml(P<0.001)。
  • PsA患者芳基酯酶活性124.4±33.4 μmoles/minute/ml vs 健康对照144.3±33.4 μmoles/minute/ml(P<0.001)。
  • PsA队列中芳基酯酶活性与DAS28评分相关(P=0.012)、与年龄相关(P=0.013)、与体重指数相关(P=0.042)、与代谢综合征相关(P=0.004)、与高血压相关(P=0.014)、与Framingham风险评分相关(P=0.001)。
  • PsO和PsA患者对氧磷酶活性与健康对照比较各P=0.073。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the activity of high-density lipoprotein (HDL)-associated paraoxonase 1 (PON1) in patients with psoriasis (PsO) and patients with psoriatic arthritis (PsA), and to evaluate the association of PON1 activity with the extent of disease activity and severity of the cardiovascular disease (CVD) burden in these patients. METHODS: Serum levels of paraoxonase and arylesterase activity (both measures of PON1 function in humans) were measured in patients with PsA (n = 198, 51.0% male) and patients with PsO (n = 145, 50.3% male) who were enrolled in a longitudinal psoriatic disease biorepository. Data on PsA disease activity (using the Disease Activity Score in 28 joints [DAS28], Clinical Disease Activity Index, and painful/swollen joint counts), preexistent CVD and CVD risk factors (including diabetes, dyslipidemia, hypertension, and smoking), Framingham Risk Scores for CVD, quality of life measures, and laboratory test findings (erythrocyte sedimentation rate, C-reactive protein level, and lipid profiles) were recorded. RESULTS: Serum arylesterase activities were significantly lower in patients with PsO and patients with PsA (mean ± SD 111.1 ± 25.5 μmoles/minute/ml and 124.4 ± 33.4 μmoles/minute/ml, respectively) compared to healthy controls (144.3 ± 33.4 μmoles/minute/ml) (each P < 0.001 versus healthy controls). Serum arylesterase activity decreased in parallel with increasing levels of disease activity (DAS28 scores, P = 0.012), older age (P = 0.013), higher body mass index (P = 0.042), greater incidence of metabolic syndrome (P = 0.004) and hypertension (P = 0.014), and worsening Framingham Risk Scores (P = 0.001). However, no correlation was seen between serum arylesterase activity and the extent of disease activity or CVD burden in patients with PsO. Serum paraoxonase activity trended lower both in patients with PsO and in patients with PsA (each P = 0.073 versus healthy controls). However, no association was seen between serum paraoxonase activity and the extent of disease activity or CVD burden in either of the patient cohorts. CONCLUSION: PON1 activity is decreased in psoriatic diseases. In the PsA cohort, decreases in arylesterase activity correlated with increasing severity of joint disease and CVD burden. Arylesterase activity, as compared to paraoxonase activity, appeared to serve as a more sensitive predictor of preexisting CV risk factors in the PsA cohort. However, this correlation was not observed in the PsO population.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Husni ME, Wilson Tang WH, Lucke M, et al. Correlation of High-Density Lipoprotein-Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease. Arthritis Rheumatol. 2018. PMID: 29569857. doi:10.1002/art.40499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。